388 related articles for article (PubMed ID: 33139055)
1. Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors.
Lang I; Liu D; Fritsch H; Taube T; Chizhikov E; Liptai B
Clin Ther; 2020 Nov; 42(11):2214-2224. PubMed ID: 33139055
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
Lin CC; Su WC; Yen CJ; Hsu CH; Su WP; Yeh KH; Lu YS; Cheng AL; Huang DC; Fritsch H; Voss F; Taube T; Yang JC
Br J Cancer; 2014 May; 110(10):2434-40. PubMed ID: 24755882
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.
Kobayashi Y; Yamauchi T; Kiyoi H; Sakura T; Hata T; Ando K; Watabe A; Harada A; Taube T; Miyazaki Y; Naoe T
Cancer Sci; 2015 Nov; 106(11):1590-5. PubMed ID: 26471242
[TBL] [Abstract][Full Text] [Related]
6. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
de Braud F; Cascinu S; Spitaleri G; Pilz K; Clementi L; Liu D; Sikken P; De Pas T
Ann Oncol; 2015 Nov; 26(11):2341-6. PubMed ID: 26395347
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
Nokihara H; Yamada Y; Fujiwara Y; Yamamoto N; Wakui H; Nakamichi S; Kitazono S; Inoue K; Harada A; Taube T; Takeuchi Y; Tamura T
Invest New Drugs; 2016 Feb; 34(1):66-74. PubMed ID: 26627079
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
[TBL] [Abstract][Full Text] [Related]
10. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
Stadler WM; Vaughn DJ; Sonpavde G; Vogelzang NJ; Tagawa ST; Petrylak DP; Rosen P; Lin CC; Mahoney J; Modi S; Lee P; Ernstoff MS; Su WC; Spira A; Pilz K; Vinisko R; Schloss C; Fritsch H; Zhao C; Carducci MA
Cancer; 2014 Apr; 120(7):976-82. PubMed ID: 24339028
[TBL] [Abstract][Full Text] [Related]
11. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
Schöffski P; Awada A; Dumez H; Gil T; Bartholomeus S; Wolter P; Taton M; Fritsch H; Glomb P; Munzert G
Eur J Cancer; 2012 Jan; 48(2):179-86. PubMed ID: 22119200
[TBL] [Abstract][Full Text] [Related]
12. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
Dirix L; Swaisland H; Verheul HM; Rottey S; Leunen K; Jerusalem G; Rolfo C; Nielsen D; Molife LR; Kristeleit R; Vos-Geelen J; Mau-Sørensen M; Soetekouw P; van Herpen C; Fielding A; So K; Bannister W; Plummer R
Clin Ther; 2016 Oct; 38(10):2286-2299. PubMed ID: 27745744
[TBL] [Abstract][Full Text] [Related]
13. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
[TBL] [Abstract][Full Text] [Related]
14. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
[TBL] [Abstract][Full Text] [Related]
15. Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
Wu CP; Hsieh CH; Hsiao SH; Luo SY; Su CY; Li YQ; Huang YH; Huang CW; Hsu SC
Mol Pharm; 2015 Nov; 12(11):3885-95. PubMed ID: 26412161
[TBL] [Abstract][Full Text] [Related]
16. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors.
Yim H
Anticancer Drugs; 2013 Nov; 24(10):999-1006. PubMed ID: 23949254
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
[TBL] [Abstract][Full Text] [Related]
18. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Lin SF; Lin JD; Yeh CN; Huang YT; Chou TC; Wong RJ
Endocr Relat Cancer; 2019 Aug; 26(8):727-738. PubMed ID: 31189135
[TBL] [Abstract][Full Text] [Related]
19. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
20. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
